Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-533-8 | CAS number: 4904-61-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Inhalation toxicity of cyclododecatriene in rats.
- Author:
- Bamberger JR, Scott RS, Kelly DP, Kennedy GL jr. and Elliott GS
- Year:
- 1 999
- Bibliographic source:
- Drug Chem. Toxicol. 22, 435-454.
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 996
- Report date:
- 1996
Materials and methods
- Principles of method if other than guideline:
- Method: as described in the reference (Bamberger et al)
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- 1,5,9-Cyclododecatriene
- IUPAC Name:
- 1,5,9-Cyclododecatriene
- Details on test material:
- 1,5,9-cyclododecatriene of DuPont Nylon, Victoria (Texas, USA);
Purity approximately 100%
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Remarks:
- Crl:CD(R)(SD)BR
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Strain: Crl:CD(R)(SD)BR
- Source: Charles River Breeding Laboratories, Raleigh (USA)
- Age: ca. 8 weeks
- Weight at study initiation: ca. 245 g (mean)
further information : see reference (Bamberger et al)
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Remarks on MMAD:
- MMAD / GSD: Particle size: vapour at 5 and 50 ppm;
aerosol at 260 ppm; particle size: MMAD 3.5 or 3.7 um, 35 or 36% of particles < 3 um; 98 or 99% of particles < 10 um - Details on inhalation exposure:
- see reference
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- -analysed by gas chromatography and gravimetric analysis in 60 min intervalls
- Duration of treatment / exposure:
- 2 weeks
- Frequency of treatment:
- 6 hours/day, 5 days/week, total 9 exposures
Doses / concentrationsopen allclose all
- Dose / conc.:
- 5 ppm
- Remarks:
- 33.4 mg/m3; 5 +/- 0 ppm (analytical concentration)
- Dose / conc.:
- 50 ppm
- Remarks:
- 334 mg/m3; 51 +/- 1.0 ppm (analytical concentration)
- Dose / conc.:
- 260 ppm
- Remarks:
- 1740 mg/m3; 260 +/- 5.7 ppm (analytical concentration)
- No. of animals per sex per dose:
- 10 per group
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Number of animals: 10 animals per group
- 2 groups per concentration:
1 for standard toxicological evaluations
1 for neurotoxicity testing
-Post-exposure period: 2 weeks (half of the animals)
- SATELLITE GROUPS AND REASONS THEY WERE ADDED: neurotoxicity
Examinations
- Observations and examinations performed and frequency:
- - Clinical signs: groupwise during exposure, individually after each exposure
- Mortality: before / during / after exposure
- Body weight: before each exposure; daily except weekends during recovery period
- Haematology: end of exposure period
- Biochemistry: end of exposure period
- Urinalysis: end of exposure period - Sacrifice and pathology:
- ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
-5 animals per group sacrificed 1 day after last exposure; other animals sacrificed after (additional) 14 days of recovery
- Macroscopic: weights of liver, kidneys, lungs, testes, brain; examination of liver, kidneys, lungs, duodenum, heart, spleen, brain (cerebrum, midbrain, cerebellum, medulla / pons), spinal cord, stomach, jejunum, ileum, pancreas, cecum, colon, rectum, mesenteric lymph node, thymus, adrenal glands, sciatic nerve, thyroid gland, parathyroid glands, trachea, esophagus, pharynx / larynx, eyes, prostate, seminal vesicles, urinary bladder, testes epididymides, sternum (with bone marrow), nose; samples of all plus of gross lesions were saved
- Microscopic: control and high dose animals sacrificed without recovery period: all organs listed above (macroscopic examination); animals from other dose groups sacrificed without recovery and control and high dose animals sacrificed after recovery: nose, pharynx / larynx, lungs, liver, kidneys - Other examinations:
- OTHER EXAMINATIONS:
Neurotoxicity groups Functional observational battery (FOB) of tests + motor activity (MA) evaluations immediately after 4th and 9th exposures; Neuropathology evaluation in 6/10 control and high dose animals after 9th exposure - Statistics:
- - Mean, standard deviation, standard error;
- Incidences: Cochran-Armitage test for trend;
- Body & organ weights: one-way analysis of variance;
- Pairwise comparison with controls: Dunnett's test
- Homogeneity of variances: Bartlett's test
- Clinical pathology: one-way analysis of variance, Bartlett's test; Dunnett's test for comparison of means to control; Kruskal-Wallis test and Mann-Whitney U test when Bartlett's test showed significance (p<0.005)
- FOB: Cochran-Armitage test for trend, Fisher's exact test for significance of deviations from control
- Other test in neurobehavioral evaluations: Bartlett's test for homogeneity (p<0.005), univariate analysis of variance, Shapiro-Wilk's test, Levene's test, Kruskal-Wallis followed by Dunn's test, block (all p<0.05)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Irregular respiration in the high dose group. Other clinical observations occurred sporadically in all groups including controls and were considered incidental.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- significantly reduced at >= 50 ppm, reversible
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Compound-related or biologically adverse changes did not occur during this study.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Compound-related or biologically adverse changes did not occur during this study.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Statistically significant or biologically adverse changes did not occur during this study.
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- A diminished or absent response to an alerting stimulus was observed in the high dose group. Mean foot splay was significantly decreased on days 4 and 9 in the high dose group. The incidence of defecation was decreased in the 50 and 260 ppm groups during the motor activity assessments. Beyond this, there were no statistically significant or toxicologically remarkable neurobehavioral differences between the control and treatment groups.
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related changes were observed. (Absolute but not relative lung weights were reduced in the high dose group.)
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Effects only occurred in the nasal tissue of the high dose group. Minimal degeneration / necrosis of olfactory epithelium occurred in the anterior portion of the nose of 4/5 rats exposed to 260 ppm. This lesion was observed neither in the 260 ppm recovery group, which suggests reversibility, nor in the lower dosed groups.
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Effect level:
- 33.4 mg/m³ air
- Sex:
- male
- Basis for effect level:
- other: no adverse effects observed
- Dose descriptor:
- LOAEC
- Effect level:
- 334 mg/m³ air
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.